Dementia research and advance consent: it is not about critical interests
Tom Buller presents a rich and thoughtful proposal for using advance directives in the context of research.1 He argues that the arguments presented in support of advance directives within the context of treatment also count within the context of research. Furthermore, he argues that research partici...
| Authors: | ; |
|---|---|
| Tipo de documento: | Recurso Electrónico Artigo |
| Idioma: | Inglês |
| Verificar disponibilidade: | HBZ Gateway |
| Journals Online & Print: | Carregar...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Publicado em: |
BMJ Publ.
2015
|
| Em: |
Journal of medical ethics
Ano: 2015, Volume: 41, Número: 8, Páginas: 708-709 |
| Acesso em linha: |
Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| Resumo: | Tom Buller presents a rich and thoughtful proposal for using advance directives in the context of research.1 He argues that the arguments presented in support of advance directives within the context of treatment also count within the context of research. Furthermore, he argues that research participation can be a critical interest and, therefore, continues to exist during the process of dementia, and furthermore, that a critical interest should overrule experiential interests, e.g, the experience of burden, during the research trial. We appreciate his contribution to the debate on advance directives and agree with his general claim that advance directives in the context of dementia research are valuable. However, we disagree with the statement that research and treatment do not differ significantly. Moreover, we argue that labelling research participation a ‘critical interest’ is too strong a claim for most people. We will provide more convincing arguments for the use of advance research directives and suggest how the value of advance research directives should be understood in practice.Buller is right in arguing that it is a pity advance directives are not used more frequently within the context of research. Research with people who suffer from dementia is important and we should search for morally acceptable means to increase the research opportunities in this group. Biomedical research, however, differs not just gradually, but fundamentally from the treatment context, because of its aims: the main aim of treatment is to benefit the patients, whereas … |
|---|---|
| ISSN: | 1473-4257 |
| Obras secundárias: | Enthalten in: Journal of medical ethics
|
| Persistent identifiers: | DOI: 10.1136/medethics-2014-102445 |